S01LA05 - Aflibercept |
Not porphyrinogenic |
NP |
Rationale
Aflibercept is a fusion protein and is not metabolized by CYP enzymes. No potential porphyrinogenic effects are expected.
Chemical description
Aflibercept is a recombinant fusion protein.
Therapeutic characteristics
Aflibercept is indicated for the treatment of neovascular (wet) age-related macular degeneration. Visual impairment due to macular degeneration secondary to retinal vein occlusion, diabetic macular oedema or due to myopic choroidal neovascularization.
Aflibercept is administered by intravitreal injections.
Hepatic exposure
A small amount of the drug enters the systemic circulation (Avary 2014).
Metabolism and pharmakokinetics
Free aflibercept binds to vascular endothelial growth factor to form a stable, inert complex. As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism (SPC).
The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept (drugbank).
References
- Scientific articles
- Avary RL et al. systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmology. 2014; 98 (12): 1636-1641. PMID 24795335. #3204
- Drug reference publications
- DrugBank. Aflibercept. #3205
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eylea. #3206
Similar drugs
© NAPOS 2024